^
Association details:
| Biomarker: | DDR |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of Olaparib and Durvalumab in Prostate Cancer
Excerpt:
Molecular evidence of DDR deleterious mutations (somatic or germline), including BRCA1, BRCA2, ATM, CHEK2, FANCA, RAD51C, RAD51D, PALB2, BRIP1, BARD1, or CDK12. Mutations may be truncating, splice site mutations, missense or homozygous deletions.
Trial ID:
